View Future GrowthMindBio Therapeutics 過去の業績過去 基準チェック /06MindBio Therapeuticsは6.7%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで36.2%毎年増加している。売上は減少しており、年平均67.1%の割合である。主要情報6.71%収益成長率109.86%EPS成長率Biotechs 業界の成長17.04%収益成長率-67.06%株主資本利益率n/aネット・マージンn/a前回の決算情報31 Mar 2026最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Jun 05MindBio Therapeutics Corp. Launches Intox AI for Validation and TestingMindBio Therapeutics Corp. has launched its lead commercial software Intox AI for validation and testing. MindBio’s enterprise solution for intoxication and fatigue detection, Intox AI enables new analytical capabilities to detect Cocaine, Cannabis, Alcohol, Psychedelics, Narcotic use and human fatigue from voice. Intox AI is a category changer in drug use and fatigue detection in high-risk industries where sobriety and alertness is an essential health and safety requirement that saves lives. The technology will be deployed to the Edge AI Kiosks that are due for initial prototype manufacturing completion shortly. The Company is targeting industries for commercialisation that have pressure to scale up drug and alcohol testing and where testing is mandated by regulators, such as the mining industry, aviation and construction, heavy transport, law enforcement and where high volume testing at scale for a variety of drugs and alcohol and human fatigue presents major challenges for management. The current systems for drug and alcohol testing involve a mouth swab test and breathalyser. These tests are time consuming, costly on a per test basis, unhygienic and environmentally harmful due to the quantity of plastic use and waste disposal. MindBio’s Voice AI solution aims to provide quick scanning for intoxication and removes these problems from legacy drug testing procedures. MindBio’s solution aims to deliver enhanced efficiency and testing at scale, not possible with current systems. The Company is on track to deliver its first prototype testing kiosks shortly and is delighted the core software is ready for testing and validation.お知らせ • May 11MindBio Therapeutics Corp Develops Fatigue Prediction Model Using Speech Analytics And AIMindBio Therapeutics Corp. commercializing AI-driven voice analytics for drug and alcohol intoxication detection, has developed a fatigue recognition and detection technology using an analysis of voice and the Company’s proprietary AI. The fatigue module will be added to the Company’s Edge AI Intoxication Detection Kiosks as an add on commercial feature designed to predict and detect fatigue in high risk industries such as aviation, road transport and mining, where sobriety and alertness is paramount to safety. In a world first claim by the Company, in its recent patent application titled “Detection of Neurologically Active Substances and Fatigue in a Human by Analysis of Voice Characteristics”, the technology aims to predict intoxication from a range of substances plus fatigue, in an add on to the Company’s anticipated commercial offering which is on track for initial commercial testing in late Second Quarter, 2026. The technology processes human voice audio signals using a short sentence or pangram to identify an individual potentially affected by a neurologically active substance, or by fatigue. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.お知らせ • May 07MindBio Therapeutics Corp. Develops Cross-Language AI Speech Analytics Capability for Intoxication DetectionMindBio Therapeutics Corp. announced the Company has developed a cross-language speech model for the detection of drug and alcohol intoxication. The language agnostic model is a game changer for the non-invasive detection of a range of neurologically active substances from a voice recording across cultures and languages. The technology being developed by MindBio is a game changer for intoxication detection where drug and alcohol testing is mandated by regulators, such as the mining industry, aviation and construction and where high volume testing at scale for a variety of drugs and alcohol presents major challenges for management, is time consuming, physically invasive and expensive. MindBio has developed an AI model currently being integrated into an Edge AI touchscreen kiosk, that can detect a range of neurologically active substances that impair cognition and performance. The technology is a game changer for the scalable detection of substance use in workplace health, safety and law enforcement. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.お知らせ • May 01MindBio Therapeutics Corp Files Patent Applications For Voice and AI Drug and Alcohol Intoxication Detection TechnologyMindBio Therapeutics Corp. had filed patent applications for its technology that uses voice and AI to detect intoxication. The technology developed by MindBio is a game changer for intoxication detection, particularly where drug and alcohol testing is mandated by regulators, such as the mining, aviation and construction industries and in law enforcement where high-volume testing at scale for a variety of drugs and alcohol presents major challenges, is time consuming, physically invasive and expensive. In a world first, MindBio has developed an AI model that powers its Edge AI Intoxication Detection Kiosks, using over 50 million data points to predict drug and alcohol intoxication with remarkable reliability and accuracy, just by using the human voice. The Company’s novel discoveries that have led to its patent application filings, allow it to use its prediction technology to detect a range of substances that effect the central nervous system and human cognition and performance. The Company also announced that it is on track for the delivery of its hardware and software solution, an Edge AI touchscreen kiosk for commercial testing, specifically for the mining and aviation industries by the end of Second Quarter, 2026. MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.お知らせ • Apr 14MindBio Therapeutics Corp. Deploys New Technology Intox Collect And Expands CNS Drug Detection Capabilities With Voice And Facial RecognitionMindBio Therapeutics Corp. had completed the development of new technology Intox Collect which has enabled the Company to rapidly scale its collection and analysis of data samples (including voice and facial recognition data) from a wide range of substances when consumed. Intox Collect is a novel software which has enhanced the Company’s data collection, testing and analytical capabilities for a range of stimulants and depressants of the human central nervous system. In a world first, MindBio has developed an AI model that uses over 50 million data points, (with that number expected to triple in the coming months) to predict drug and alcohol intoxication with remarkable accuracy, just by using the human voice. The completion of the Company’s new Intox Collect™ software allows the company to expand its prediction technology to a range of substances that effect the central nervous system, which when consumed impair cognition and human performance. The technology is a game changer for intoxication detection, particularly where drug and alcohol testing is mandated by regulators, such as the mining, aviation and construction industries and where high volume testing at scale for a variety of drugs and alcohol presents major challenges, is time consuming, physically invasive and expensive. The Company recently announced that a prototype design for its new Edge AI Hardware-Software solution is nearing completion and its kiosk touch screen devices will be ready for testing late in the Second Quarter, 2026.お知らせ • Apr 03MindBio Therapeutics Corp. announced that it has received CAD 1.437829 million in fundingOn April 1, 2026, MindBio Therapeutics Corp closed the transaction. The company announced that it has issued 2,396,381 units at a price of CAD 0.60 per Unit for gross proceeds of 1,437,828.87. In connection with completion of the Offering, the Company paid aggregate cash fees of CAD 70,183.97 and issued an aggregate of 116,973 non-transferable Share purchase warrants to eligible third-parties who introduced subscribers to the Offering. Each Finder Warrant entitles the holder thereof to acquire one Share at a price of CAD 0.80 for a period of thirty-six months after the date of issue, subject to accelerated expiry in the event the closing price of the Shares on the CSE exceeds $1.00 for ten consecutive trading days. All securities issued in connection with the Offering are subject to restrictions on resale for a period of four months-and-one-day in accordance with applicable securities laws. The Offering remains subject to final regulatory approvals.お知らせ • Feb 19MindBio Therapeutics Corp. announced that it expects to receive CAD 0.65 million in fundingMindBio Therapeutics Corp non-brokered private placement to issue 1,083,333 units at an issue price of CAD 0.60 for the proceeds of CAD 649,999.8 on February 19, 2026. Each unit will consist of one common share of the company and one share purchase warrant. Each warrant will entitle the holder to acquire an additional share at a price of CAD 0.80 for a period of 36 months following closing of the offering. In connection with completion of the offering, the company will pay finders' fees to eligible third parties which have introduced subscribers to the offering. All securities issued in connection with the offering will be subject to restrictions on resale for a period of four months and one day in accordance with applicable securities laws. Completion of the offering remains subject to final board and regulatory approvals.収支内訳MindBio Therapeutics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:MBQI.F 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費31 Mar 260-77031 Dec 250-65030 Sep 250-43030 Jun 250-32031 Mar 25-1-20031 Dec 240-11030 Sep 24001030 Jun 24001031 Mar 241-43031 Dec 230-43030 Sep 230-43030 Jun 230-430質の高い収益: MBQI.Fは現在利益が出ていません。利益率の向上: MBQI.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MBQI.Fは利益を出していないが、過去 5 年間で年間6.7%の割合で損失を削減してきた。成長の加速: MBQI.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: MBQI.Fは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 54.5% ) と比較することは困難です。株主資本利益率高いROE: MBQI.Fの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/16 07:02終値2026/06/12 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MindBio Therapeutics Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jun 05MindBio Therapeutics Corp. Launches Intox AI for Validation and TestingMindBio Therapeutics Corp. has launched its lead commercial software Intox AI for validation and testing. MindBio’s enterprise solution for intoxication and fatigue detection, Intox AI enables new analytical capabilities to detect Cocaine, Cannabis, Alcohol, Psychedelics, Narcotic use and human fatigue from voice. Intox AI is a category changer in drug use and fatigue detection in high-risk industries where sobriety and alertness is an essential health and safety requirement that saves lives. The technology will be deployed to the Edge AI Kiosks that are due for initial prototype manufacturing completion shortly. The Company is targeting industries for commercialisation that have pressure to scale up drug and alcohol testing and where testing is mandated by regulators, such as the mining industry, aviation and construction, heavy transport, law enforcement and where high volume testing at scale for a variety of drugs and alcohol and human fatigue presents major challenges for management. The current systems for drug and alcohol testing involve a mouth swab test and breathalyser. These tests are time consuming, costly on a per test basis, unhygienic and environmentally harmful due to the quantity of plastic use and waste disposal. MindBio’s Voice AI solution aims to provide quick scanning for intoxication and removes these problems from legacy drug testing procedures. MindBio’s solution aims to deliver enhanced efficiency and testing at scale, not possible with current systems. The Company is on track to deliver its first prototype testing kiosks shortly and is delighted the core software is ready for testing and validation.
お知らせ • May 11MindBio Therapeutics Corp Develops Fatigue Prediction Model Using Speech Analytics And AIMindBio Therapeutics Corp. commercializing AI-driven voice analytics for drug and alcohol intoxication detection, has developed a fatigue recognition and detection technology using an analysis of voice and the Company’s proprietary AI. The fatigue module will be added to the Company’s Edge AI Intoxication Detection Kiosks as an add on commercial feature designed to predict and detect fatigue in high risk industries such as aviation, road transport and mining, where sobriety and alertness is paramount to safety. In a world first claim by the Company, in its recent patent application titled “Detection of Neurologically Active Substances and Fatigue in a Human by Analysis of Voice Characteristics”, the technology aims to predict intoxication from a range of substances plus fatigue, in an add on to the Company’s anticipated commercial offering which is on track for initial commercial testing in late Second Quarter, 2026. The technology processes human voice audio signals using a short sentence or pangram to identify an individual potentially affected by a neurologically active substance, or by fatigue. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
お知らせ • May 07MindBio Therapeutics Corp. Develops Cross-Language AI Speech Analytics Capability for Intoxication DetectionMindBio Therapeutics Corp. announced the Company has developed a cross-language speech model for the detection of drug and alcohol intoxication. The language agnostic model is a game changer for the non-invasive detection of a range of neurologically active substances from a voice recording across cultures and languages. The technology being developed by MindBio is a game changer for intoxication detection where drug and alcohol testing is mandated by regulators, such as the mining industry, aviation and construction and where high volume testing at scale for a variety of drugs and alcohol presents major challenges for management, is time consuming, physically invasive and expensive. MindBio has developed an AI model currently being integrated into an Edge AI touchscreen kiosk, that can detect a range of neurologically active substances that impair cognition and performance. The technology is a game changer for the scalable detection of substance use in workplace health, safety and law enforcement. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
お知らせ • May 01MindBio Therapeutics Corp Files Patent Applications For Voice and AI Drug and Alcohol Intoxication Detection TechnologyMindBio Therapeutics Corp. had filed patent applications for its technology that uses voice and AI to detect intoxication. The technology developed by MindBio is a game changer for intoxication detection, particularly where drug and alcohol testing is mandated by regulators, such as the mining, aviation and construction industries and in law enforcement where high-volume testing at scale for a variety of drugs and alcohol presents major challenges, is time consuming, physically invasive and expensive. In a world first, MindBio has developed an AI model that powers its Edge AI Intoxication Detection Kiosks, using over 50 million data points to predict drug and alcohol intoxication with remarkable reliability and accuracy, just by using the human voice. The Company’s novel discoveries that have led to its patent application filings, allow it to use its prediction technology to detect a range of substances that effect the central nervous system and human cognition and performance. The Company also announced that it is on track for the delivery of its hardware and software solution, an Edge AI touchscreen kiosk for commercial testing, specifically for the mining and aviation industries by the end of Second Quarter, 2026. MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement.
お知らせ • Apr 14MindBio Therapeutics Corp. Deploys New Technology Intox Collect And Expands CNS Drug Detection Capabilities With Voice And Facial RecognitionMindBio Therapeutics Corp. had completed the development of new technology Intox Collect which has enabled the Company to rapidly scale its collection and analysis of data samples (including voice and facial recognition data) from a wide range of substances when consumed. Intox Collect is a novel software which has enhanced the Company’s data collection, testing and analytical capabilities for a range of stimulants and depressants of the human central nervous system. In a world first, MindBio has developed an AI model that uses over 50 million data points, (with that number expected to triple in the coming months) to predict drug and alcohol intoxication with remarkable accuracy, just by using the human voice. The completion of the Company’s new Intox Collect™ software allows the company to expand its prediction technology to a range of substances that effect the central nervous system, which when consumed impair cognition and human performance. The technology is a game changer for intoxication detection, particularly where drug and alcohol testing is mandated by regulators, such as the mining, aviation and construction industries and where high volume testing at scale for a variety of drugs and alcohol presents major challenges, is time consuming, physically invasive and expensive. The Company recently announced that a prototype design for its new Edge AI Hardware-Software solution is nearing completion and its kiosk touch screen devices will be ready for testing late in the Second Quarter, 2026.
お知らせ • Apr 03MindBio Therapeutics Corp. announced that it has received CAD 1.437829 million in fundingOn April 1, 2026, MindBio Therapeutics Corp closed the transaction. The company announced that it has issued 2,396,381 units at a price of CAD 0.60 per Unit for gross proceeds of 1,437,828.87. In connection with completion of the Offering, the Company paid aggregate cash fees of CAD 70,183.97 and issued an aggregate of 116,973 non-transferable Share purchase warrants to eligible third-parties who introduced subscribers to the Offering. Each Finder Warrant entitles the holder thereof to acquire one Share at a price of CAD 0.80 for a period of thirty-six months after the date of issue, subject to accelerated expiry in the event the closing price of the Shares on the CSE exceeds $1.00 for ten consecutive trading days. All securities issued in connection with the Offering are subject to restrictions on resale for a period of four months-and-one-day in accordance with applicable securities laws. The Offering remains subject to final regulatory approvals.
お知らせ • Feb 19MindBio Therapeutics Corp. announced that it expects to receive CAD 0.65 million in fundingMindBio Therapeutics Corp non-brokered private placement to issue 1,083,333 units at an issue price of CAD 0.60 for the proceeds of CAD 649,999.8 on February 19, 2026. Each unit will consist of one common share of the company and one share purchase warrant. Each warrant will entitle the holder to acquire an additional share at a price of CAD 0.80 for a period of 36 months following closing of the offering. In connection with completion of the offering, the company will pay finders' fees to eligible third parties which have introduced subscribers to the offering. All securities issued in connection with the offering will be subject to restrictions on resale for a period of four months and one day in accordance with applicable securities laws. Completion of the offering remains subject to final board and regulatory approvals.